Congenital Diarrhea and Enteropathies Panel
Use
This panel is intended for individuals with relevant clinical features or a suspected diagnosis of congenital diarrhea and enteropathies. It is also suitable for those with symptom onset within the first few months of life and individuals with chronic diarrhea not likely due to environmental or infectious causes.
Special Instructions
This test is not cleared or approved by the US Food and Drug Administration. It is developed and validated by PreventionGenetics following CAP and CLIA regulations. STAT testing is available, which reduces the standard TAT at an additional charge.
Limitations
The performance of this test may be limited by the quality and integrity of the DNA sample. Variants in intergenic regions that lie outside targeted regions may not be detected. Real-time events like large deletions, insertions, or complex rearrangements may not be captured accurately. The test is not intended for prenatal diagnosis.
New York Approved
Methodology
NGS (Exome)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided